iACP: a sequence-based tool for identifying anticancer peptides.

Chen W, Ding H, Feng P, Lin H, Chou KC. · 2016

Read iACP: a sequence-based tool for identifying anticancer peptides. by Chen W, Ding H, Feng P, Lin H, Chou KC. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4941358.txt.

Introduction

Wei Chen and four co-authors build iACP, a program that flags anticancer peptides from their letter sequence alone. Their paper appeared in Oncotarget in 2016. Anticancer peptides are short protein chains that can kill cancer cells with fewer side effects than standard drugs. Lab testing of each candidate is slow, so a fast screen helps. The tool studies pairs of amino acids spaced at set gaps in the sequence, a pattern the team tuned for this task.

Strict cross validation tests showed iACP beat the earlier predictors on both accuracy and stability. The team put the tool on a public web server for free use. A user pastes a sequence and gets a verdict on whether it looks like an anticancer peptide. The authors present the server as a first filter for drug hunting. Promising hits still need lab proof before any medical use can be claimed.

Catalog record

CREATORChen W, Ding H, Feng P, Lin H, Chou KC.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE61 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4941358

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

iACP: a sequence-based tool for identifying anticancer peptides By Wei Chen, Hui Ding, Pengmian Feng, Hao Lin, Kuo-Chen Chou Published in: Oncotarget DOI: 10.18632/oncotarget.7815 ABSTRACT Abstract Cancer remains a major killer worldwide. Traditional methods of cancer treatment are expensive and have some deleterious side effects on normal cells. Fortunately, the discovery of anticancer peptides (ACPs) has paved a new way for cancer treatment. With the explosive growth of peptide sequences generated in the post genomic age, it is highly desired to develop computational methods for rapidly and effectively identifying ACPs, so as to speed up their application in treating cancer. Here we report a sequence-based predictor called iACP developed by the approach of optimizing the g-gap dipeptide components. It was demonstrated by rigorous cross-validations that the new predictor remarkably outperformed the existing predictors for the same purpose in both overall accuracy and stability. For the convenience of most experimental scientists, a publicly accessible web-server for iACP has been established at http://lin.uestc.edu.cn/server/iACP, by which users can easily obtain their desired results. Keywords: anticancer peptides, PseAAC, g-gap dipeptide mode, incremental feature selection, iACP webserver INTRODUCTION Millions of people have been killed by cancer globally every year [1]. Although cancer can be treated with the combination of radiation therapy, targeted therapy and chemotherapy, these physical or chemical methods are expensive and have some deleterious side effects on normal cells [2, 3]. It has also been demonstrated that cancer cells begin to exhibit resistance towards current anticancer drugs [4]. Therefore, it is urgent to develop novel anticancer agents. Because anticancer peptides (ACPs) do not impair the normal body physiological functions, they open promising perspective for the cancer treatment [5, 6]. The discovery of ACPs has provided an alternative approach to treat cancer. Despite some potential drawbacks during their development process, such as low in vivo stability and high costs for production [5], ACPs have some unique and exceptional advantages. This is because ACPs are naturally occurring biologics, and hence are safer than synthetic drugs, as well as have a greater efficacy, selectivity and specificity. In addition to the advantage of peptide drugs having no toxicity in-vivo under the normal physiological condition [7–9], ACPs are small peptides and usually contain 5 to 30 amino acids. Also, since ACPs are cationic in nature [10], they can interact with the anionic cell membrane components of cancer cells and then selectively kill cancer cells [10, 11]. Over the last decade, many peptide-based strategies against various tumor types have been pre-clinically used [12, 13], indicating that ACPs may become promising candidates for cancer treatments. In view of the fact that the clinical trials of ACPs are still under development, studies on ACPs action mechanisms are crucial for cancer treatment. Therefore, it is important for both basic research and drug development to discriminate ACPs from natural and artificially designed peptides. Unfortunately, experimental identification and development of novel ACPs is extremely cost-ineffective and time-consuming. Besides, only few of them have been successfully translated into clinics [14]. Therefore, it is necessary to resort to computational methods. Actually, using amino acid composition and binary profiles as the input of support vector machine (SVM), Tyagi et al. [15] proposed a model to identify ACPs. Shortly afterwards, Hajisharifi et al. [16], using Chou's pseudo amino acid composition and the local alignment kernel based method, also proposed a model to do the same. Both methods yielded quite encouraging results and have indeed played an important role in stimulating the development of this area. In considering the importance of ACPs to human beings’ health, the present study was initiated to further enhance the identification quality by proposing a new and more powerful predictor for the same purpose. Furthermore, to maximize the convenience for most experimental scientists, we have provided a user-friendly web-server and a step-by-step guide by which users can easily obtain their desired results without the need to go through the mathematical equations, which, however, are useful for those who want to use the current mathematical approach to develop other predictors in computational biology. As demonstrated in a series of recent publications [17–29], to establish a really useful sequence-based statistical predictor for a biological system and also to make the presentation logically more clear and easier to follow, according to Chou's 5-step guidelines [30] we should make the following five procedures crystal clear: (1) benchmark dataset; (2) sample representation; (3) operation engine; (4) cross validation; (5) web-server. Below, let us elaborate how to deal with the five steps one-by one. To match the Journal's style, however, they are not exactly following the above order. RESULTS AND DISCUSSION A new and more powerful sequence-based method, called iACP, was developed for predicting anti-cancer peptides. Comparison with other existing methods The jackknife success rates achieved by iACP on the benchmark dataset (see Supporting Information S1) are given in Table 1, where for facilitating comparison, the rates reported by Hajisharifi et al. [16] are also listed. As we can see from Table 1, iACP outperformed the method by Hajisharifi et al.'s method in both Acc and MCC, indicating that the current predictor is not only able to achieve higher overall success rate, but also more stable. [Table: A comparison of the current method iACP with hajisharifi et al.'s method [16] on the same benchmark dataset (Online Supporting Information S1)] It should be noted that the rates reported by Hajisharifi et al. [16] were obtained by the 5-fold cross-validation rather than the rigorous jackknife rest and hence would lack objectiveness [30]. For the current case, the benchmark dataset contains 138 ACPs and 206 non-ACPs. According to the Eqs.28 and 29 in the review article [30], the number of possible combinations for conducting the 5-cross-validation would be more than 1074. Therefore, the rates reported by Hajisharifi et al. [16] were derived from an extremely small fraction of the possible combinations, and hence could not avoid arbitrariness. If the iACP predictor was also tested by the 5-fold cross-validation on the same benchmark dataset, however, we obtained Acc = 94.77% and MCC = 0.893, which are also remarkably higher than the corresponding rates by Hajisharifi et al. To further verify the power of the current predictor, a comparison was also made between iACP and Tyagi et al.'s method AntiCP [15] on a same independent dataset (see Eq.2 and Supporting Information S2). As mentioned in the “Benchmark Dataset” section, none of the independent data occurs in the dataset used to train the current predictor iACP. Accordingly, there is no memory advantage [31] whatsoever to iACP. The results thus obtained are given in Table 2, from which we can observe the following. The overall accuracy Acc and Matthews correlation coefficient MCC obtained by iACP are 92.67% and 0.88, respectively. They are remarkably higher than the corresponding rates obtained by the AntiCP method [15], which are 50.00% and 0.00 for its module 1 and 66.33% and 0.36 for its module 2, respectively. The detailed predictive results thus obtained are given in Supporting Information S3. The above results indicate that the proposed predictor iACP is indeed quite promising or at least can play a complimentary role to the existing state-of-the art methods in this area [15, 16]. [Table: A comparison of the current method with the one by

Read the complete text